Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations

Fabio Marroni, Paolo Aretini, Emma D'Andre, Maria Adelaide Caligo, Laura Cortesi, Alessandra Viel, Enrico Ricevuto, Marco Montagna, Giovanna Cipollini, Massimo Federico, Manuela Santarosa, Paolo Marchetti, Joan E. Bailey-Wilson, Generoso Bevilacqua, Giovanni Parmigiani, Silvano Presciuttini

Research output: Contribution to journalArticle

Abstract

Accurate estimates of breast and ovarian cancer penetrance in BRCA1/2 mutation carriers are crucial in genetic counseling. Estimation is difficult because of the low frequency of mutated alleles and the often-uncertain mechanisms of family ascertainment. We estimated the penetrances of breast and ovarian cancers in carriers of BRCA1/2 mutations by maximizing the retrospective likelihood of the genetic model, given the observed test results, in 568 Italian families screened for germline mutations. The software BRCAPRO was used as a probability calculation tool in a Markov Chain Monte Carlo approach. Breast cancer penetrances were 27% (95% CI 20-34%) at age 50 years and 39% (27-52%) at age 70 in BRCA1 carriers, and 26% (0.18-0.34%) at age 50 and 44% (29-58%) at age 70 in BRCA2 carriers, and ovarian cancer penetrances were 14% (7-22%) at age 50 and 43% (21 -66%) at age 70 in BRCA1 carriers and 3% (0-7%) at age 50 and 15% (4-26%) at age 70 in BRCA2 carriers. The new model gave a better fit than the current default in BRCAPRO, the likelihood being 70 log units greater; in addition, the observed numbers of mutations in families stratified by gene and by cancer profile were not significantly different from those expected. Our new penetrance functions are appropriate for predicting breast cancer risk, and for determining the probability of carrying BRCA1/2 mutations, in people who are presently referred to genetic counseling in Italy. Our approach could lead to country-customized versions of the BRCAPRO software by providing appropriate population-specific estimates.

Original languageEnglish (US)
Pages (from-to)899-906
Number of pages8
JournalEuropean Journal of Human Genetics
Volume12
Issue number11
DOIs
StatePublished - Nov 2004

Fingerprint

Penetrance
Ovarian Neoplasms
Breast Neoplasms
Mutation
Genetic Counseling
Software
Markov Chains
Germ-Line Mutation
Neoplasm Genes
Genetic Models
Gene Frequency
Italy
Population

Keywords

  • BRCA1
  • BRCA2
  • BRCAPRO
  • Genetic testing
  • Penetrance
  • Predictive models

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Marroni, F., Aretini, P., D'Andre, E., Caligo, M. A., Cortesi, L., Viel, A., ... Presciuttini, S. (2004). Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. European Journal of Human Genetics, 12(11), 899-906. https://doi.org/10.1038/sj.ejhg.5201256

Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. / Marroni, Fabio; Aretini, Paolo; D'Andre, Emma; Caligo, Maria Adelaide; Cortesi, Laura; Viel, Alessandra; Ricevuto, Enrico; Montagna, Marco; Cipollini, Giovanna; Federico, Massimo; Santarosa, Manuela; Marchetti, Paolo; Bailey-Wilson, Joan E.; Bevilacqua, Generoso; Parmigiani, Giovanni; Presciuttini, Silvano.

In: European Journal of Human Genetics, Vol. 12, No. 11, 11.2004, p. 899-906.

Research output: Contribution to journalArticle

Marroni, F, Aretini, P, D'Andre, E, Caligo, MA, Cortesi, L, Viel, A, Ricevuto, E, Montagna, M, Cipollini, G, Federico, M, Santarosa, M, Marchetti, P, Bailey-Wilson, JE, Bevilacqua, G, Parmigiani, G & Presciuttini, S 2004, 'Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations', European Journal of Human Genetics, vol. 12, no. 11, pp. 899-906. https://doi.org/10.1038/sj.ejhg.5201256
Marroni, Fabio ; Aretini, Paolo ; D'Andre, Emma ; Caligo, Maria Adelaide ; Cortesi, Laura ; Viel, Alessandra ; Ricevuto, Enrico ; Montagna, Marco ; Cipollini, Giovanna ; Federico, Massimo ; Santarosa, Manuela ; Marchetti, Paolo ; Bailey-Wilson, Joan E. ; Bevilacqua, Generoso ; Parmigiani, Giovanni ; Presciuttini, Silvano. / Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. In: European Journal of Human Genetics. 2004 ; Vol. 12, No. 11. pp. 899-906.
@article{8f3f06952bb4432b9185fcb4bc967d7a,
title = "Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations",
abstract = "Accurate estimates of breast and ovarian cancer penetrance in BRCA1/2 mutation carriers are crucial in genetic counseling. Estimation is difficult because of the low frequency of mutated alleles and the often-uncertain mechanisms of family ascertainment. We estimated the penetrances of breast and ovarian cancers in carriers of BRCA1/2 mutations by maximizing the retrospective likelihood of the genetic model, given the observed test results, in 568 Italian families screened for germline mutations. The software BRCAPRO was used as a probability calculation tool in a Markov Chain Monte Carlo approach. Breast cancer penetrances were 27{\%} (95{\%} CI 20-34{\%}) at age 50 years and 39{\%} (27-52{\%}) at age 70 in BRCA1 carriers, and 26{\%} (0.18-0.34{\%}) at age 50 and 44{\%} (29-58{\%}) at age 70 in BRCA2 carriers, and ovarian cancer penetrances were 14{\%} (7-22{\%}) at age 50 and 43{\%} (21 -66{\%}) at age 70 in BRCA1 carriers and 3{\%} (0-7{\%}) at age 50 and 15{\%} (4-26{\%}) at age 70 in BRCA2 carriers. The new model gave a better fit than the current default in BRCAPRO, the likelihood being 70 log units greater; in addition, the observed numbers of mutations in families stratified by gene and by cancer profile were not significantly different from those expected. Our new penetrance functions are appropriate for predicting breast cancer risk, and for determining the probability of carrying BRCA1/2 mutations, in people who are presently referred to genetic counseling in Italy. Our approach could lead to country-customized versions of the BRCAPRO software by providing appropriate population-specific estimates.",
keywords = "BRCA1, BRCA2, BRCAPRO, Genetic testing, Penetrance, Predictive models",
author = "Fabio Marroni and Paolo Aretini and Emma D'Andre and Caligo, {Maria Adelaide} and Laura Cortesi and Alessandra Viel and Enrico Ricevuto and Marco Montagna and Giovanna Cipollini and Massimo Federico and Manuela Santarosa and Paolo Marchetti and Bailey-Wilson, {Joan E.} and Generoso Bevilacqua and Giovanni Parmigiani and Silvano Presciuttini",
year = "2004",
month = "11",
doi = "10.1038/sj.ejhg.5201256",
language = "English (US)",
volume = "12",
pages = "899--906",
journal = "European Journal of Human Genetics",
issn = "1018-4813",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations

AU - Marroni, Fabio

AU - Aretini, Paolo

AU - D'Andre, Emma

AU - Caligo, Maria Adelaide

AU - Cortesi, Laura

AU - Viel, Alessandra

AU - Ricevuto, Enrico

AU - Montagna, Marco

AU - Cipollini, Giovanna

AU - Federico, Massimo

AU - Santarosa, Manuela

AU - Marchetti, Paolo

AU - Bailey-Wilson, Joan E.

AU - Bevilacqua, Generoso

AU - Parmigiani, Giovanni

AU - Presciuttini, Silvano

PY - 2004/11

Y1 - 2004/11

N2 - Accurate estimates of breast and ovarian cancer penetrance in BRCA1/2 mutation carriers are crucial in genetic counseling. Estimation is difficult because of the low frequency of mutated alleles and the often-uncertain mechanisms of family ascertainment. We estimated the penetrances of breast and ovarian cancers in carriers of BRCA1/2 mutations by maximizing the retrospective likelihood of the genetic model, given the observed test results, in 568 Italian families screened for germline mutations. The software BRCAPRO was used as a probability calculation tool in a Markov Chain Monte Carlo approach. Breast cancer penetrances were 27% (95% CI 20-34%) at age 50 years and 39% (27-52%) at age 70 in BRCA1 carriers, and 26% (0.18-0.34%) at age 50 and 44% (29-58%) at age 70 in BRCA2 carriers, and ovarian cancer penetrances were 14% (7-22%) at age 50 and 43% (21 -66%) at age 70 in BRCA1 carriers and 3% (0-7%) at age 50 and 15% (4-26%) at age 70 in BRCA2 carriers. The new model gave a better fit than the current default in BRCAPRO, the likelihood being 70 log units greater; in addition, the observed numbers of mutations in families stratified by gene and by cancer profile were not significantly different from those expected. Our new penetrance functions are appropriate for predicting breast cancer risk, and for determining the probability of carrying BRCA1/2 mutations, in people who are presently referred to genetic counseling in Italy. Our approach could lead to country-customized versions of the BRCAPRO software by providing appropriate population-specific estimates.

AB - Accurate estimates of breast and ovarian cancer penetrance in BRCA1/2 mutation carriers are crucial in genetic counseling. Estimation is difficult because of the low frequency of mutated alleles and the often-uncertain mechanisms of family ascertainment. We estimated the penetrances of breast and ovarian cancers in carriers of BRCA1/2 mutations by maximizing the retrospective likelihood of the genetic model, given the observed test results, in 568 Italian families screened for germline mutations. The software BRCAPRO was used as a probability calculation tool in a Markov Chain Monte Carlo approach. Breast cancer penetrances were 27% (95% CI 20-34%) at age 50 years and 39% (27-52%) at age 70 in BRCA1 carriers, and 26% (0.18-0.34%) at age 50 and 44% (29-58%) at age 70 in BRCA2 carriers, and ovarian cancer penetrances were 14% (7-22%) at age 50 and 43% (21 -66%) at age 70 in BRCA1 carriers and 3% (0-7%) at age 50 and 15% (4-26%) at age 70 in BRCA2 carriers. The new model gave a better fit than the current default in BRCAPRO, the likelihood being 70 log units greater; in addition, the observed numbers of mutations in families stratified by gene and by cancer profile were not significantly different from those expected. Our new penetrance functions are appropriate for predicting breast cancer risk, and for determining the probability of carrying BRCA1/2 mutations, in people who are presently referred to genetic counseling in Italy. Our approach could lead to country-customized versions of the BRCAPRO software by providing appropriate population-specific estimates.

KW - BRCA1

KW - BRCA2

KW - BRCAPRO

KW - Genetic testing

KW - Penetrance

KW - Predictive models

UR - http://www.scopus.com/inward/record.url?scp=7744225684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7744225684&partnerID=8YFLogxK

U2 - 10.1038/sj.ejhg.5201256

DO - 10.1038/sj.ejhg.5201256

M3 - Article

C2 - 15340362

AN - SCOPUS:7744225684

VL - 12

SP - 899

EP - 906

JO - European Journal of Human Genetics

JF - European Journal of Human Genetics

SN - 1018-4813

IS - 11

ER -